Literature DB >> 12512186

Zygomycosis.

Corina E Gonzalez1, Michael G Rinaldi, Alan M Sugar.   

Abstract

Zygomycosis, an uncommon but frequently fatal mycosis caused by fungi of the class Zygomycetes, develops most commonly as an opportunistic disease. Successful therapy involves a combined approach based on early diagnosis, prompt institution of medical therapy, and extensive surgical debridement of all devitalized tissue. Given the rarity of this condition, novel therapeutic strategies have been limited and only tested on an individual basis. The use of high-dose lipid formulations of amphotericin B, prompt reversal of the underlying predisposing condition, and hyperbaric oxygen are the most common strategies that have shown potential value in the treatment of zygomycosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12512186     DOI: 10.1016/s0891-5520(02)00037-5

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  32 in total

Review 1.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin's disease who had undergone allogeneic hematopoietic stem cell transplantation.

Authors:  Michelle A Barron; Margaret Lay; Nancy E Madinger
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Mucormycosis spondylodiscitis after lumbar disc puncture.

Authors:  Fei Chen; Guohua Lü; Yijun Kang; Zeming Ma; Chang Lu; Bin Wang; Jin Li; Jun Liu; Haisheng Li
Journal:  Eur Spine J       Date:  2005-11-18       Impact factor: 3.134

5.  Real-time PCR method for detection of zygomycetes.

Authors:  D Jane Hata; Seanne P Buckwalter; Bobbi S Pritt; Glenn D Roberts; Nancy L Wengenack
Journal:  J Clin Microbiol       Date:  2008-05-14       Impact factor: 5.948

6.  Intraabdominal zygomycosis caused by Syncephalastrum racemosum infection successfully treated with partial surgical debridement and high-dose amphotericin B lipid complex.

Authors:  Sanmarié Schlebusch; David F M Looke
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

Review 7.  Zygomycosis: the re-emerging fungal infection.

Authors:  M Chayakulkeeree; M A Ghannoum; J R Perfect
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

8.  Clinical experience in invasive fungal infections.

Authors:  Patrícia Pacheco; Ana Sofia Ventura; Teresa Branco; Lucília Gonçalves; Célia Carvalho
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

9.  Identification of fungal pathogens in a patient with acute myelogenic leukemia using a pathogen detection array technology.

Authors:  Sagarika Banerjee; Kristen N Peck; Michael D Feldman; Mindy G Schuster; James C Alwine; Erle S Robertson
Journal:  Cancer Biol Ther       Date:  2016-04-02       Impact factor: 4.742

10.  Potential antifungal effects of human platelets against zygomycetes in vitro.

Authors:  Susanne Perkhofer; Barbara Kainzner; Beate E Kehrel; Manfred P Dierich; Walter Nussbaumer; Cornelia Lass-Flörl
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.